Table 4.
Variable | Medication Group | p Value | η2 (Effect Size) | ||||||
---|---|---|---|---|---|---|---|---|---|
N03 (n = 2) |
N05 (n = 6) |
N06 (n = 29) |
N03, N05 (n = 5) |
N03, N06 (n = 7) |
N05, N06 (n = 21) |
N03, N05, N06 (n = 15) |
|||
BMI (kg/m2) | 28.6 ± 2.9 | 29.8 ± 6.0 | 30.2 ± 7.1 | 32.3 ± 5.8 | 32.8 ± 3.5 | 34.4 ± 5.5 | 35.7 ± 6.3 | 0.078 | 0.132 |
Neck circumference (cm) | 42.0 ± 8.5 | 43.3 ± 7.3 | 38.5 ± 4.3 | 40.2 ± 4.8 | 42.9 ± 5.9 | 42.0 ± 4.0 | 41.1 ± 5.2 | 0.128 | 0.120 |
Waist circumference (cm) | 109.5 ± 3.5 | 113.3 ± 12.3 | 106.1 ± 16.0 | 115.2 ± 16.8 | 117.1 ± 13.2 | 117.0 ± 11.6 | 119.8 ± 10.6 | 0.046 | 0.151 |
Hip circumference (cm) | 103.5 ± 7.8 | 110.8 ± 8.2 | 108.8 ± 11.4 | 112.8 ± 4.8 | 116.4 ± 9.3 | 116.4 ± 14.2 | 118.9 ± 11.6 | 0.091 | 0.131 |
FEV1 (%) | 113.2 ± 26.2 | 82..4 ± 19.3 | 97.0 ± 12.7 | 86.2 ± 15.2 | 97.3 ± 15.6 | 90.4 ± 18.2 | 87.2 ± 16.1 | 0.091 | 0.129 |
FVC (%) | 110.6 ± 5.7 | 81.1 ± 16.6 | 97.8 ± 14.3 | 83.1 ± 14.7 | 96.9 ± 15.7 | 89.1 ± 18.4 | 85.0 ± 14.9 | 0.027 | 0.165 |
AHI | 31.8 ± 0.0 | 55.8 ± 32.0 | 31.3 ± 21.6 | 53.1 ± 50.9 | 50.1 ± 32.2 | 24.0 ± 18.9 | 32.1 ± 26.5 | 0.058 | 0.146 |
meanSaO2 (%) | 95.0 ± 0.0 | 88.7 ± 4.4 | 92.6 ± 2.5 | 92.9 ± 2.4 | 92.6 ± 1.9 | 92.3 ± 3.0 | 91.3 ± 3.2 | 0.077 | 0.138 |
minSaO2 (%) | 93.0 ± 0.0 | 76.0 ± 13.3 | 85.5 ± 5.7 | 83.2 ± 8.3 | 81.7 ± 7.3 | 83.3 ± 6.7 | 80.9 ± 10.7 | 0.131 | 0.120 |
time with SaO2 < 90% (min) | 0.0 ± 0.0 | 58.3 ± 44.5 | 8.6 ± 14.6 | 14.6 ± 15.7 | 14.2 ± 12.8 | 18.3 ± 31.4 | 25.2 ± 32.8 | 0.006 | 0.211 |
AHI: Apnea-Hypopnea Index, BMI: Body Mass Index, FVC: Forced Vital Capacity, FEV1: Forced Expiratory Volume in 1s, SaO2: Oxyhemoglobin Saturation. Considering the existence of multiple comparisons, the Bonferroni correction (i.e., alpha level/number of comparisons, i.e., 0.05/10) was applied setting the significance level, respectively, to p = 0.005.